CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 344 enrolled
Drug / intervention
LJPC-501 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02338843
NCT02338843Phase 3Completed
CompareCT.gov

A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)

La Jolla Pharmaceutical Company·interventional·Posted Jan 14, 2015·Updated Mar 27, 2018

In Brief

A Phase 3 clinical trial evaluating LJPC-501 and Placebo for Catecholamine-resistant Hypotension (CRH) and 3 related conditions. Completed, enrolled 344 participants across 115 sites in 10 countries.

Detailed Summary

This is a Phase 3, double-blind, randomized study of LJPC-501 (angiotensin II) in adult patients diagnosed with catecholamine-resistant hypotension (CRH) conducted in multiple centers globally.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCatecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
CountriesAustralia, Belgium, Canada, Finland, France, Germany, New Zealand, Switzerland, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 14, 2015
Enrollment StartMar 1, 2015
Primary CompletionDec 1, 2016
Study CompletionFeb 18, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.5 years ago

Interventions

LJPC-501drug

Treatment arm

Placebodrug

PBO